US Patent

US9284300 — Pyridazinone derivatives

Formulation · Assigned to Merck Patent GmbH · Expires 2028-04-29 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects pyridazinone derivatives and their uses as inhibitors of tyrosine kinases, specifically Met kinase, in tumor treatment methods.

USPTO Abstract

Compounds of formula (I) and their uses as inhibitors of tyrosine kinases, in particular Met kinase, and their employment in methods for the treatment of tumors.

Drugs covered by this patent

tepotinib-hydrochloride (TEPOTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: US9284300
Jurisdiction: US
Classification: Formulation
Expires: 2028-04-29
Drug substance claim: No
Drug product claim: Yes
Assignee: Merck Patent GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.